NBW Capital LLC Has $3.83 Million Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)

NBW Capital LLC boosted its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 25.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,886 shares of the biotechnology company's stock after purchasing an additional 8,821 shares during the period. NBW Capital LLC owned approximately 0.07% of Blueprint Medicines worth $3,828,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BPMC. Empirical Asset Management LLC acquired a new stake in shares of Blueprint Medicines in the fourth quarter valued at $2,348,000. Stephens Inc. AR bought a new stake in Blueprint Medicines in the fourth quarter worth about $321,000. Massachusetts Financial Services Co. MA lifted its holdings in Blueprint Medicines by 48.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company's stock valued at $23,332,000 after acquiring an additional 82,693 shares during the last quarter. Entropy Technologies LP bought a new position in shares of Blueprint Medicines during the 3rd quarter valued at about $999,000. Finally, KBC Group NV grew its stake in shares of Blueprint Medicines by 63.9% in the 4th quarter. KBC Group NV now owns 2,625 shares of the biotechnology company's stock worth $229,000 after purchasing an additional 1,023 shares during the last quarter.

Blueprint Medicines Stock Down 1.6 %

NASDAQ:BPMC traded down $1.42 during mid-day trading on Friday, reaching $87.12. The stock had a trading volume of 908,608 shares, compared to its average volume of 1,021,582. The stock has a market cap of $5.57 billion, a P/E ratio of -80.67 and a beta of 0.62. The business's 50 day moving average is $99.43 and its 200 day moving average is $94.27. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. Blueprint Medicines Co. has a fifty-two week low of $80.68 and a fifty-two week high of $121.90.

Remove Ads

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, sell-side analysts predict that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on BPMC shares. StockNews.com lowered shares of Blueprint Medicines from a "hold" rating to a "sell" rating in a research note on Monday. JPMorgan Chase & Co. increased their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Piper Sandler lifted their target price on Blueprint Medicines from $109.00 to $119.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $133.00 target price on shares of Blueprint Medicines in a report on Thursday, February 13th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $125.00 price target on shares of Blueprint Medicines in a research report on Friday, February 14th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Blueprint Medicines currently has an average rating of "Moderate Buy" and an average price target of $125.21.

Insiders Place Their Bets

In other news, CEO Kate Haviland sold 1,446 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the transaction, the chief executive officer now owns 149,378 shares of the company's stock, valued at approximately $16,467,430.72. This represents a 0.96 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey W. Albers sold 15,000 shares of the firm's stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $89.77, for a total value of $1,346,550.00. Following the completion of the transaction, the director now directly owns 157,557 shares in the company, valued at $14,143,891.89. The trade was a 8.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 48,427 shares of company stock valued at $4,837,801 over the last three months. 4.21% of the stock is currently owned by insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.